WO2019088057A1 - Dérivé d'anilide et son utilisation médicale - Google Patents

Dérivé d'anilide et son utilisation médicale Download PDF

Info

Publication number
WO2019088057A1
WO2019088057A1 PCT/JP2018/040211 JP2018040211W WO2019088057A1 WO 2019088057 A1 WO2019088057 A1 WO 2019088057A1 JP 2018040211 W JP2018040211 W JP 2018040211W WO 2019088057 A1 WO2019088057 A1 WO 2019088057A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
reference example
reaction
mmol
derivative
Prior art date
Application number
PCT/JP2018/040211
Other languages
English (en)
Japanese (ja)
Inventor
雄輝 松村
英喜 高橋
新之助 林
マーシャル バレット
真幸 星
拓実 青木
和也 大角
慎也 横坂
目黒　裕之
こずえ 高垣
戒能　美枝
Original Assignee
東レ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東レ株式会社 filed Critical 東レ株式会社
Priority to JP2018560051A priority Critical patent/JPWO2019088057A1/ja
Publication of WO2019088057A1 publication Critical patent/WO2019088057A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Definitions

  • the present invention relates to anilide derivatives and their pharmaceutical uses.
  • Autoimmune disease is a general term for diseases in which excessive immune reaction causes symptoms by attacking normal cells and tissues of the patient.
  • diseases in which excessive immune reaction causes symptoms by attacking normal cells and tissues of the patient.
  • multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory Intestinal diseases, ankylosing spondylitis, uveitis or polymyalgia rheumatica can be mentioned.
  • Non-patent Documents 1 and 2 Various mechanisms have been proposed for the onset and progression of autoimmune diseases, and one of them is Th17 cells, which is a subset of helper T cells, and IL-17, which is an inflammatory cytokine that it produces. It is known to play an important role in the onset and progression of autoimmune diseases (Non-patent Documents 1 and 2).
  • IL-17 acts on various cells such as fibroblasts, epithelial cells, vascular endothelial cells and macrophages, and is involved in induction of inflammatory cytokines, chemokines, metalloproteases and other inflammatory mediators and neutrophil migration. ing. Therefore, if it is possible to suppress the production or function of IL-17, a strong anti-inflammatory effect is considered to be exerted, and clinical trials of anti-IL-17 antibodies with indications for various autoimmune diseases are conducted. It is done.
  • ROR ⁇ nuclear receptor retinoid-related orphan receptor ⁇
  • Non-patent Document 5 In patients with autoimmune diseases (multiple sclerosis, psoriasis, systemic lupus erythematosus etc.), it has been reported that the expression level of ROR ⁇ in peripheral blood mononuclear cells shows a high value as compared with healthy people (Non-patent Document 5) And 6). It is reported that in ROR ⁇ knockout mice, the pathological condition of mouse experimental autoimmune encephalomyelitis model, which is an animal model of multiple sclerosis, is suppressed, and symptoms of autoimmune diseases such as colitis are suppressed. (Non-Patent Documents 3 and 7).
  • ROR ⁇ antagonists which are compounds that inhibit the binding of ROR ⁇ to coactivators, are expected to be useful as therapeutic or prophylactic agents for autoimmune diseases.
  • N- (5- (N- (4- (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl) phenyl) sulfamoyl) has hitherto been described.
  • Non-patent Document 9 6- (2-chloro-4-methylphenyl) -3- (4-cyclopropyl-5- (3-neopentylcyclobutyl) Substituted azole derivatives such as isoxazol-3-yl) -5-oxohexanoic acid (Patent Document 1), N- (2-chloro-2 '-(trifluoromethoxy)-[1,1'-biphenyl ]-4-yl) -2- (4- (methylsulfonyl) phenyl) acetamide (Patent Document 2), 2- (4- (4- (4- (ethylsulfonyl) phenyl) acetamide) phenyl (Nyl) -N- (4-fluorophenyl) -2-methylpropanamide (Patent Document 3), N- (3-chloro-4- (1,1,1,3,3,3-he
  • Non-patent document 10 3-substituted Examples of compounds having anilide structure such as N- (4-((3,4-dihydroisoquinolin-2 (1H) -yl) phenyl) acetamide include fibroblast growth factor receptor 1 inhibitors and fibroblasts N- (4-((3,4-Dihydroisoquinolin-2 (1H) -yl) methyl) -3- (trifluoro) as a growth factor receptor 2 inhibitor (Thyl) phenyl) -3- (isoquinolin-4-ylethynyl) -4-methylbenzamide and the like have been reported (Patent Document 7), such as 3-substituted N- (4- (isoindoline-2-ylmethyl) phenyl) acetamide and the like.
  • Patent Document 7 such as 3-substituted N- (4- (isoindoline-2-ylmethyl) phenyl) acetamide and the like.
  • N- (4- (isoindoline-2-ylmethyl) -3- (trifluoro) as a fibroblast growth factor receptor 1 inhibitor and a fibroblast growth factor receptor 2 inhibitor (Methyl) phenyl) -3- (isoquinolin-4-ylethynyl) -4-methylbenzamide and the like have been reported (Patent Document 7), and anilide such as 3-substituted N- (4- (indoline-1-ylmethyl) phenyl) acetamide and the like
  • Patent Document 8 As a compound having a structure, 5'-acetylamino-2 '-(5-carbamimidiine) as a serine protease inhibitor 2,3-dihydro - indol-1-ylmethyl) - but-2-carboxylic acid and the like have been reported (Patent Document 8), are not disclosed or suggested about the effect on ROR ⁇ of these compounds.
  • this invention aims at providing the novel compound which has ROR (gamma) antagonist activity and exhibits a therapeutic effect or a preventive effect with respect to autoimmune diseases, such as psoriasis.
  • the present invention provides an anilide derivative represented by the following general formula (I) or a hydrate thereof, or a pharmacologically acceptable salt thereof.
  • R 1 represents a halogen atom
  • R 2 represents a hydrogen atom or a methyl group (in this methyl group, 1 to 3 arbitrary hydrogen atoms may be substituted with a halogen atom)
  • m represents 0 or 1
  • n represents 0 or 1
  • p represents 1 or 2;
  • R 1 is a fluorine atom or a chlorine atom
  • R 2 is a hydrogen atom or a methyl group (wherein the methyl group is any one to three hydrogen atoms)
  • the atom is a fluorine atom or a chlorine atom.
  • R 1 is a fluorine atom or a chlorine atom
  • R 2 is a methyl group (the methyl group is an optional hydrogen atom of 1 to 3) Is more preferably substituted by a fluorine atom).
  • ROR ⁇ antagonist activity can be expected, and further, excellent therapeutic effect or preventive effect in autoimmune diseases such as psoriasis can be expected.
  • R 1 is a fluorine atom or a chlorine atom
  • R 2 is a trifluoromethyl group
  • n is 1
  • p is 2
  • the present invention also provides medicaments and ROR ⁇ antagonists comprising, as an active ingredient, the anilide derivative represented by the above general formula (I) or a hydrate thereof, or a pharmacologically acceptable salt thereof.
  • the above-mentioned medicine is preferably a therapeutic agent or a preventive agent for an autoimmune disease, and as a therapeutic agent or a preventive agent for the above-mentioned autoimmune disease, a therapeutic agent or a preventive agent for psoriasis is more preferable.
  • the anilide derivative of the present invention or a hydrate thereof, or a pharmacologically acceptable salt thereof can effectively suppress the function of ROR ⁇ because it has ROR ⁇ antagonist activity, and can be used as a therapeutic agent or agent for autoimmune diseases It can be used as an agent.
  • the anilide derivative of the present invention is characterized by being represented by the following general formula (I). [Wherein, R 1 represents a halogen atom, and R 2 represents a hydrogen atom or a methyl group (in this methyl group, 1 to 3 arbitrary hydrogen atoms may be substituted with a halogen atom)] And m represents 0 or 1; n represents 0 or 1; p represents 1 or 2; ]
  • halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • methyl group in the methyl group, one to three arbitrary hydrogen atoms may be substituted with a halogen atom
  • a halogen atom means that one to three arbitrary hydrogen atoms of the methyl group are Each independently represents a group which may be substituted by the above-mentioned halogen atom, and examples thereof include a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group or a trichloromethyl group.
  • methyl group in the methyl group, any one to three optional hydrogen atoms may be substituted with a fluorine atom or a chlorine atom
  • methyl group means any one to three hydrogens of the methyl group.
  • Each of the atoms independently represents a group which may be substituted with a fluorine atom or a chlorine atom, and examples thereof include a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group and a trichloromethyl group.
  • methyl group in the methyl group, any one to three optional hydrogen atoms may be substituted with a fluorine atom
  • methyl group means that one to three optional hydrogen atoms of the methyl group are It means a group which may be substituted by a fluorine atom, and specifically means a methyl group, a fluoromethyl group, a difluoromethyl group or a trifluoromethyl group.
  • the anilide derivative represented by the general formula (I) or a hydrate thereof or a pharmacologically acceptable salt thereof refers to the anilide derivative represented by the general formula (I), a compound represented by the general formula (I) The pharmacologically acceptable hydrate of the anilide derivative shown, the pharmacologically acceptable salt of the anilide derivative shown by the general formula (I) or the pharmacologically acceptable hydrate of the anilide derivative shown by the general formula (I) Mean salt.
  • R 1 is preferably a fluorine atom or a chlorine atom.
  • R 2 is preferably a hydrogen atom or a methyl group (in the methyl group, one to three arbitrary hydrogen atoms may be substituted with a fluorine atom or a chlorine atom), and a methyl group (the above-mentioned methyl group)
  • the methyl group is more preferably 1 to 3 arbitrary hydrogen atoms which may be substituted with a fluorine atom), and still more preferably a trifluoromethyl group.
  • N is preferably 1.
  • P is preferably 2.
  • n and p for example, a combination in which n is 1 and p is 2 (tetrahydroisoquinoline ring), a combination in which n is 0 and p is 2 (indoline ring), or n is 1 And p is 1 (isoindoline ring).
  • R 2 when n is 1 and p is 2 (tetrahydroisoquinoline ring), R 2 is substituted at the 6- or 7-position of the tetrahydroisoquinoline ring When n is 0 and p is 2 (indoline ring), R 2 is preferably substituted at the 5-position of the indoline ring, n is 1 and p is When is 1 (isoindoline ring), R 2 is preferably substituted at the 5-position of the isoindoline ring.
  • any aspect can be selected and combined for the preferred R 1 , the preferred R 2 , the preferred n described above, and the preferred p described above.
  • the compounds listed in Table 1 also include their hydrates and their pharmacologically acceptable salts and mixtures thereof.
  • anilide derivative represented by the above general formula (I) not only a single isomer but also a mixture of a racemate and a mixture of diastereomers as well as a single isomer when the stereoisomer exists is also represented by the above general formula (I) It includes in the anilide derivative shown by these.
  • Stepoisomer refers to a compound having the same chemical structure but different arrangement in three-dimensional space, such as, for example, conformer, rotamer, tautomer, optical isomer, diastereomer Etc.
  • the anilide derivative represented by the above general formula (I) may be labeled with one or more isotopes, and the isotopes to be labeled include, for example, 2 H, 3 H, 13 C, 14 C, 15 N, 15 O, 18 O and / or 125 I can be mentioned.
  • Examples of the "pharmaceutically acceptable salt" of the anilide derivative represented by the above general formula (I) include salts with inorganic acids or salts with organic acids.
  • Examples of salts with inorganic acids include hydrochlorides, sulfates, nitrates, hydrobromides, hydroiodides or phosphates, and salts with organic acids include, for example, oxalic acid.
  • the anilide derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof may be an anhydride, or may form a solvate such as a hydrate.
  • a solvate a pharmacologically acceptable solvate is preferable.
  • the pharmacologically acceptable solvate may be either hydrate or non-hydrate, but hydrate is preferred.
  • the solvent constituting the solvate include alcohol solvents such as methanol, ethanol or n-propanol, N, N-dimethylformamide (hereinafter, DMF), dimethyl sulfoxide (hereinafter, DMSO) or water.
  • anilide derivative represented by the above general formula (I) can be produced by an appropriate method based on the characteristics derived from the basic skeleton and the type of substituent. Starting materials and reagents used for producing these compounds can be generally purchased or can be produced by known methods.
  • the anilide derivative (I) and the intermediates and starting materials used for its preparation can be isolated and purified by known means.
  • Known means for isolation and purification include, for example, solvent extraction, reprecipitation, recrystallization or chromatography.
  • each optical isomer and diastereomer can be obtained as a single optically active substance by a known method.
  • known methods include, for example, crystallization, enzymatic resolution or chiral chromatography.
  • the crystallization can be carried out according to a known method (for example, Brittain, H. G., "Polymorphism in Pharmaceutical Solids, Second Edition", CRC Press) or a method analogous thereto.
  • THF tetrahydrofuran
  • 1,4-dioxane 1,4-dioxane
  • diethyl ether Ether solvents such as tert-butyl methyl ether or anisole, methanol, ethanol, 2-methoxyethanol, 2-ethoxyethanol, n-propanol, 2-propanol, 2-methyl-1-propanol, n-butanol, 2-butanol Alcohol solvents such as 3-methyl-1-butanol, n-pentanol or ethylene glycol, aromatic hydrocarbon solvents such as toluene, xylene, cumene or tetralin DMF, N, N-dimethylacetamide, formamide, N -Methyl pyrrolidone, D Aprotic polar solvents such as SO or sulfolane,
  • a protective group may be introduced into these groups, and after the reaction, the protective group is optionally deprotected.
  • the target compound can be obtained by
  • an alkylcarbonyl group having 2 to 6 carbon atoms eg, acetyl group
  • benzoyl group an alkyloxycarbonyl group having 2 to 8 carbon atoms (eg, tert-butoxycarbonyl group or benzyloxy) And a carbonyl group
  • an aralkyl group having 7 to 10 carbon atoms eg, benzyl group
  • a phthaloyl group for example, an alkylcarbonyl group having 2 to 6 carbon atoms (eg, acetyl group), benzoyl group, an alkyloxycarbonyl group having 2 to 8 carbon atoms (eg, tert-butoxycarbonyl group or benzyloxy) And a carbonyl group), an aralkyl group having 7 to 10 carbon atoms (eg, benzyl group) or a phthaloyl group.
  • an alkylcarbonyl group having 2 to 6 carbon atoms eg,
  • Examples of the protecting group for the carboxyl group include, for example, an alkyl group having 1 to 6 carbon atoms (eg, methyl group, ethyl group or tert-butyl group) or an aralkyl group having 7 to 10 carbon atoms (eg, benzyl group).
  • the deprotection of the protective group varies depending on the type of protective group, but is carried out according to known methods (for example, Greene, TW, "Greene's Protective Groups in Organic Synthesis", Wiley-Interscience) or a method according thereto. be able to.
  • the anilide derivative (I) can be obtained, for example, by condensation reaction of an aniline derivative (II) with a phenylacetic acid derivative (III) in the presence of a condensing agent and a base as shown in Scheme 1. [Wherein, R 1 , R 2 , m, n and p are as defined above. ]
  • the amount of phenylacetic acid derivative (III) used in the condensation reaction is preferably 0.1 to 10 equivalents, more preferably 0.5 to 3 equivalents, relative to aniline derivative (II).
  • condensing agent used for the condensation reaction examples include N, N'-dicyclohexylcarbodiimide, N-ethyl-N'-3-dimethylaminopropylcarbodiimide hydrochloride (hereinafter referred to as EDC.HCl), N, N'-carbodiimidazole ⁇ [(1-cyano-2-ethoxy-2-oxoethylidene) amino] oxy ⁇ -4-morpholinomethylene ⁇ dimethyl ammonium hexafluorophosphate (hereinafter COMU), O- (7-azabenzotriazole- 1-yl) -1,1,3,3-tetramethyluronium hexafluorophosphate (hereinafter HATU) or O- (benzotriazol-1-yl) -N, N, N ', N'-tetramethyl Although uronium hexafluorophosphate (following, HBTU) is mentioned, HATU or HBTU
  • the amount of the condensing agent used for the condensation reaction is preferably 0.5 to 10 equivalents, more preferably 1 to 3 equivalents, relative to the aniline derivative (II).
  • Examples of the base used for the condensation reaction include organic bases such as triethylamine or diisopropylethylamine, inorganic bases such as sodium hydrogencarbonate or potassium carbonate, sodium hydride, hydrogenated metal compounds such as potassium hydride or calcium hydride, methyl lithium Or an alkyllithium such as butyllithium, a lithium amide such as lithium hexamethyldisilazide or lithium diisopropylamide, or a mixture thereof, but an organic base such as triethylamine or diisopropylethylamine is preferred.
  • organic bases such as triethylamine or diisopropylethylamine
  • inorganic bases such as sodium hydrogencarbonate or potassium carbonate, sodium hydride, hydrogenated metal compounds such as potassium hydride or calcium hydride, methyl lithium Or an alkyllithium such as butyllithium, a lithium amide such as lithium hexamethyldisilazide or lithium diisopropylamide
  • the amount of the base used for the condensation reaction is preferably 0.5 to 10 equivalents, more preferably 1 to 5 equivalents based on the aniline derivative (II).
  • the aniline derivative (II) used for the condensation reaction may be a free form or a salt such as hydrochloride.
  • the reaction solvent used for the condensation reaction is appropriately selected according to the type of reagent used, etc., and is not particularly limited as long as it does not inhibit the reaction, and examples thereof include tetrahydrofuran (hereinafter, THF), 1,4-dioxane, Ether solvents such as ethylene glycol dimethyl ether or dimethoxyethane, halogen solvents such as dichloromethane, chloroform or 1,2-dichloroethane, aprotic polar solvents such as DMF or DMSO, or nitrile solvents such as acetonitrile or propionitrile
  • THF tetrahydrofuran
  • Ether solvents such as ethylene glycol dimethyl ether or dimethoxyethane
  • halogen solvents such as dichloromethane, chloroform or 1,2-dichloroethane
  • aprotic polar solvents such as DMF or DMSO
  • nitrile solvents such as acetonitrile
  • the reaction temperature of the condensation reaction is preferably 0 to 200 ° C., and more preferably 20 to 100 ° C.
  • the reaction time of the condensation reaction is appropriately selected according to the conditions such as the reaction temperature, but is preferably 1 to 30 hours.
  • the concentration at the start of the reaction of the aniline derivative (II) used for the condensation reaction is preferably 1 mmol / L to 1 mol / L.
  • the aniline derivative (II) and the phenylacetic acid derivative (III) used for the condensation reaction can be purchased or can be produced by known methods or methods analogous thereto.
  • an aniline derivative (II-a) in which m is 1 is, for example, as shown in Scheme 2, a reduction reaction of benzoic acid derivative (IV) (step 1) Then, the oxidation reaction (the second step) of the benzyl alcohol derivative (V) obtained in the first step, and subsequently, the benzaldehyde derivative (VI) obtained in the second step and the amine derivative (VII) It can be obtained by a reductive amination reaction (step 3), followed by a reduction reaction (step 4) of the nitrophenyl derivative (VIII) obtained in the third step in the presence of a metal and an acid. [Wherein, R 1 , R 2 , n and p are as defined above. ]
  • Step 1 Examples of the reducing agent used for the reduction reaction include lithium aluminum hydride, diisobutylaluminum hydride, sodium borohydride, lithium borohydride, lithium triethylborohydride or borane THF complex, but a borane THF complex is preferable .
  • the amount of reducing agent used for the reduction reaction is preferably 0.25 to 100 equivalents, and more preferably 0.5 to 10 equivalents with respect to the benzoic acid derivative (IV).
  • the reaction solvent used for the reduction reaction is appropriately selected according to the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction, and examples thereof include THF, 1,4-dioxane, ethylene glycol dimethyl ether or dimethoxyethane And ethereal solvents such as benzene and toluene; but ether solvents such as THF, 1,4-dioxane, ethylene glycol dimethyl ether and dimethoxyethane are preferable.
  • the reaction temperature of the reduction reaction is preferably -78 ° C to 100 ° C, and more preferably -30 ° C to 50 ° C.
  • the reaction time of the reduction reaction is appropriately selected depending on the conditions such as the reaction temperature, but is preferably 10 minutes to 10 hours.
  • the concentration of the benzoic acid derivative (IV) used for the reduction reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
  • the benzoic acid derivative (IV) used for the reduction reaction may be a free form or a salt such as a sodium salt.
  • the benzoic acid derivative (IV) used for the reduction reaction can be purchased or can be produced by a known method or a method analogous thereto.
  • Step 2 Examples of the oxidizing agent used for the oxidation reaction include sulfur trioxide-pyridine, activated dimethyl sulfoxide, desmartine reagent, manganese dioxide or 2,2,6,6-tetramethylpiperidine 1-oxyl (hereinafter TEMPO).
  • TEMPO 2,2,6,6-tetramethylpiperidine 1-oxyl
  • the amount of the oxidizing agent used for the oxidation reaction is preferably 0.5 to 10 equivalents, more preferably 0.8 to 5 equivalents, to the benzyl alcohol derivative (V).
  • the reaction solvent used for the oxidation reaction is appropriately selected according to the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction, and examples thereof include aromatic amine solvents such as pyridine, dichloromethane, chloroform or Chlorinated solvents such as 2-dichloroethane, ether solvents such as THF or 1,4-dioxane, nitrile solvents such as acetonitrile or propionitrile, or mixed solvents thereof.
  • aromatic amine solvents such as pyridine, dichloromethane, chloroform or Chlorinated solvents such as 2-dichloroethane, ether solvents such as THF or 1,4-dioxane, nitrile solvents such as acetonitrile or propionitrile, or mixed solvents thereof.
  • the reaction temperature of the oxidation reaction is preferably ⁇ 78 ° C. to 100 ° C., and more preferably ⁇ 78 ° C. to 60 ° C.
  • the reaction time of the oxidation reaction is appropriately selected depending on the conditions such as the reaction temperature, but is preferably 5 minutes to 72 hours, and more preferably 0.5 to 48 hours.
  • the concentration at the start of the reaction of the benzyl alcohol acid derivative (V) used for the oxidation reaction is preferably 1 mmol / L to 1 mol / L.
  • the amount of the amine derivative (VII) used for the reductive amination reaction is preferably 0.5 to 10 equivalents, more preferably 1 to 3 equivalents with respect to the benzaldehyde derivative (VI).
  • the amine derivative (VII) used for the reductive amination reaction may be a free form or a salt such as hydrochloride.
  • sodium borohydride, sodium cyanoborohydride or sodium triacetoxyborohydride can be mentioned, and sodium triacetoxyborohydride is preferable.
  • the amount of the reducing agent used for the reductive amination reaction is preferably 0.5 to 10 equivalents, more preferably 1 to 3 equivalents based on the benzaldehyde derivative (VI).
  • the reaction solvent used for the reductive amination reaction is appropriately selected according to the type of reagent used, but is not particularly limited as long as it does not inhibit the reaction, and examples thereof include alcohol solvents such as methanol and ethanol, diethyl ether And ether solvents such as THF, dimethoxyethane or 1,4-dioxane, chlorinated solvents such as dichloromethane, chloroform or 1,2-dichloroethane or mixed solvents thereof, but dichloromethane, chloroform or 1,2-dichloroethane Chlorinated solvents such as are preferred.
  • alcohol solvents such as methanol and ethanol
  • diethyl ether And ether solvents such as THF, dimethoxyethane or 1,4-dioxane
  • chlorinated solvents such as dichloromethane, chloroform or 1,2-dichloroethane or mixed solvents thereof, but dichloromethane, chloroform or 1,2-dichloroe
  • the reaction temperature of the reductive amination reaction is preferably ⁇ 78 ° C. to 200 ° C., and more preferably ⁇ 20 ° C. to 100 ° C.
  • the reaction time of the reductive amination reaction is appropriately selected depending on the conditions such as the reaction temperature, but is preferably 0.5 to 30 hours.
  • the concentration of the benzaldehyde derivative (VI) at the start of the reaction used for the reductive amination reaction is preferably 1 mmol / L to 1 mol / L.
  • the amine derivative (VII) used for the reductive amination reaction can be purchased or can be produced by a known method or a method analogous thereto.
  • Step 4 Examples of the metal used for the reduction reaction include iron powder and tin (II) chloride, with iron powder being preferred.
  • the amount of metal used for the reduction reaction is preferably 0.5 to 50 equivalents, more preferably 1 to 10 equivalents, to the nitrophenyl derivative (VIII).
  • Examples of the acid used for the reduction reaction include acetic acid, hydrochloric acid or an aqueous solution of ammonium chloride, with preference given to acetic acid or an aqueous solution of ammonium chloride.
  • the amount of the acid used for the reduction reaction is preferably 0.5 to 50 equivalents, more preferably 1 to 10 equivalents, to the nitrophenyl derivative (VIII).
  • the reaction solvent used for the reduction reaction is appropriately selected according to the type of reagent used, etc., but is not particularly limited as long as it does not inhibit the reaction, for example, alcohol solvents such as methanol or ethanol, diethyl ether, THF And ether solvents such as dimethoxyethane or 1,4-dioxane, water, or mixed solvents thereof, but alcohol solvents such as methanol or ethanol and diethyl ether, THF, dimethoxyethane or 1,4-dioxane A mixed solvent of an ether-based solvent and water is preferred.
  • the reaction temperature of the reduction reaction is preferably 0 to 200 ° C., and more preferably 50 to 150 ° C.
  • the reaction time of the reduction reaction is appropriately selected according to the conditions such as the reaction temperature, but is preferably 1 to 30 hours.
  • the concentration at the start of the reaction of the nitrophenyl derivative (VIII) used for the reduction reaction is preferably 1 mmol / L to 1 mol / L.
  • aniline derivative (II) shown in Scheme 1 aniline derivative (II-b) in which m is 0 is, for example, a fluorophenyl derivative of amine derivative (VII) in the presence of a base as shown in Scheme 3.
  • This can be obtained by the nucleophilic substitution reaction (step 1) for IX), followed by the reduction reaction (step 2) of the nitrophenyl derivative (X) obtained in the first step in the presence of a metal and an acid.
  • R 1 , R 2 , n and p are as defined above.
  • the amount of the amine derivative (VII) used for the nucleophilic substitution reaction is preferably 0.5 to 10 equivalents, more preferably 1 to 3 equivalents with respect to the fluorophenyl derivative (IX).
  • the amine derivative (VII) used for the nucleophilic substitution reaction may be in free form or may be a salt such as hydrochloride.
  • Examples of the base used for the nucleophilic substitution reaction include organic bases such as triethylamine, diisopropylethylamine or N-methylmorpholine, inorganic bases such as sodium carbonate or potassium carbonate, hydrogen such as sodium hydride, potassium hydride or calcium hydride Metal oxides, lithium amides such as lithium hexamethyldisilazide or lithium diisopropylamide, metal alkoxides such as tert-butyloxy sodium or tert-butyloxy potassium, or mixtures thereof, but triethylamine, diisopropylethylamine or N- Organic bases such as methyl morpholine or sodium hydride, metal hydride compounds such as potassium hydride or calcium hydride are preferred.
  • organic bases such as triethylamine, diisopropylethylamine or N-methylmorpholine
  • inorganic bases such as sodium carbonate or potassium carbonate
  • hydrogen such as sodium hydride, potassium hydride
  • the amount of the base used for the nucleophilic substitution reaction is preferably 0.5 to 10 equivalents, more preferably 1 to 3 equivalents, to the fluorophenyl derivative (IX).
  • the reaction solvent used for the nucleophilic substitution reaction is appropriately selected according to the type of the reagent used, etc., but is not particularly limited as long as it does not inhibit the reaction, for example, THF, 1,4-dioxane, ethylene glycol dimethyl ether Or an ether solvent such as dimethoxyethane, a nitrile solvent such as acetonitrile or propionitrile, an aromatic hydrocarbon solvent such as benzene or toluene, an aprotic polar solvent such as DMF or DMSO, water or a mixed solvent thereof Although non-polar polar solvents such as DMF or DMSO are preferred.
  • the reaction temperature of the nucleophilic substitution reaction is preferably ⁇ 78 ° C. to 200 ° C., and more preferably ⁇ 20 ° C. to 160 ° C.
  • the reaction time of the nucleophilic substitution reaction is appropriately selected according to the conditions such as the reaction temperature, but is preferably 1 to 30 hours.
  • the concentration at the start of reaction of the fluorophenyl derivative (IX) used for the nucleophilic substitution reaction is preferably 1 mmol / L to 1 mol / L.
  • the fluorophenyl derivative (IX) and the amine derivative (VII) used for the nucleophilic substitution reaction can be purchased or can be produced by a known method or a method analogous thereto.
  • Step 2 Examples of the metal used for the reduction reaction include iron powder and tin (II) chloride, with iron powder being preferred.
  • the amount of metal used for the reduction reaction is preferably 0.5 to 50 equivalents, more preferably 1 to 10 equivalents, to the nitrophenyl derivative (X).
  • Examples of the acid used for the reduction reaction include acetic acid, hydrochloric acid or an aqueous solution of ammonium chloride, with preference given to acetic acid or an aqueous solution of ammonium chloride.
  • the amount of the acid used for the reduction reaction is preferably 0.5 to 50 equivalents, more preferably 1 to 10 equivalents, to the nitrophenyl derivative (X).
  • the reaction solvent used for the reduction reaction is appropriately selected according to the type of reagent used, etc., but is not particularly limited as long as it does not inhibit the reaction, for example, alcohol solvents such as methanol or ethanol, diethyl ether, THF And ether solvents such as dimethoxyethane or 1,4-dioxane, water, or mixed solvents thereof, but alcohol solvents such as methanol or ethanol and diethyl ether, THF, dimethoxyethane or 1,4-dioxane A mixed solvent of an ether-based solvent and water is preferred.
  • the reaction temperature of the reduction reaction is preferably 0 to 200 ° C., and more preferably 50 to 150 ° C.
  • the reaction time of the reduction reaction is appropriately selected according to the conditions such as the reaction temperature, but is preferably 1 to 30 hours.
  • the concentration at the start of the reaction of the nitrophenyl derivative (X) used for the reduction reaction is preferably 1 mmol / L to 1 mol / L.
  • tetrahydroisoquinoline derivatives (VII-a) in which n is 1 and p is 2 are, for example, trifluoroacetic anhydride as shown in Scheme 4.
  • Step 2 is as defined above.
  • the amount of trifluoroacetic anhydride used for the trifluoroacetylation reaction is preferably 0.5 to 20 equivalents, more preferably 1 to 5 equivalents, with respect to phenethylamine derivative (XI).
  • the reaction solvent used for the trifluoroacetylation reaction is appropriately selected according to the type of the reagent used, but is not particularly limited as long as it does not inhibit the reaction, for example, DMF, N, N-dimethylacetamide, N -Aprotic polar solvents such as methyl-2-pyrrolidone or DMSO, ether solvents such as diethyl ether, THF, dimethoxyethane or 1,4-dioxane, ester solvents such as ethyl acetate or propyl acetate, dichloromethane, chloroform or Chlorinated solvents such as 1,2-dichloroethane or mixed solvents thereof may be mentioned, and chlorinated solvents such as dichloromethane, chloroform or 1,2-dichloroethane are preferable.
  • the reaction temperature of the trifluoroacetylation reaction is preferably -20 ° C to 100 ° C, and more preferably 0 to 50 ° C.
  • the reaction time of the trifluoroacetylation reaction is appropriately selected depending on the conditions such as the reaction temperature, but is preferably 1 to 30 hours.
  • the concentration of phenethylamine derivative (XI) used for the trifluoroacetylation reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
  • the phenethylamine derivative (XI) used for the trifluoroacetylation reaction may be a free form or a salt such as hydrochloride.
  • the phenethylamine derivative (XI) used for the trifluoroacetylation reaction can be purchased or can be produced by a known method or a method analogous thereto.
  • Step 2 The amount of paraformaldehyde used for the cyclization reaction is preferably 0.5 to 20 equivalents, more preferably 1 to 5 equivalents, relative to the trifluoroacetamide derivative (XII).
  • Examples of the acid used for the cyclization reaction include hydrochloric acid, acetic acid, trifluoroacetic acid, concentrated sulfuric acid, concentrated nitric acid, and phosphoric acid, but a mixed solution of acetic acid and concentrated sulfuric acid is preferable.
  • the amount of the acid used for the cyclization reaction is preferably 0.5 to 100 equivalents, more preferably 1 to 50 equivalents based on the trifluoroacetamide derivative (XII).
  • the reaction solvent used for the cyclization reaction is appropriately selected according to the type of the reagent used, but is not particularly limited as long as it does not inhibit the reaction, and, for example, DMF, N, N-dimethylacetamide, N-methyl- Aprotic polar solvents such as 2-pyrrolidone or DMSO, ether solvents such as diethyl ether, THF, dimethoxyethane or 1,4-dioxane, chlorinated solvents such as dichloromethane, chloroform or 1,2-dichloroethane or mixtures thereof A solvent is mentioned.
  • the reaction temperature of the cyclization reaction is preferably -20 ° C to 100 ° C, and more preferably 0 to 50 ° C.
  • the reaction time of the cyclization reaction is appropriately selected according to the conditions such as the reaction temperature, but is preferably 1 to 30 hours.
  • the concentration of the trifluoroacetamide derivative (XII) used for the cyclization reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
  • inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide or potassium carbonate, are mentioned, for example.
  • the amount of the base used for the hydrolysis reaction is preferably 0.5 to 50 equivalents, more preferably 1 to 20 equivalents based on the tetrahydroisoquinoline derivative (XIII).
  • the reaction solvent used for the hydrolysis reaction is appropriately selected according to the type of the reagent used, but is not particularly limited as long as it does not inhibit the reaction, and examples thereof include alcohol solvents such as methanol and ethanol, acetonitrile or pro Nitrile solvents such as piononitrile, aprotic polar solvents such as DMF, N, N-dimethylacetamide, N-methyl-2-pyrrolidone or DMSO, ethers such as diethyl ether, THF, dimethoxyethane or 1,4-dioxane
  • the solvent include ester solvents such as ethyl acetate or propyl acetate, chlorinated solvents such as dichloromethane, chloroform or 1,2-dichloroethane, and mixed solvents thereof, and alcohol solvents such as methanol or ethanol, DMF, N , N-dimeth Acetamide, N- methyl-2-pyrrolidone or aprotic polar solvents
  • the reaction temperature of the hydrolysis reaction is preferably -20 ° C to 200 ° C, and more preferably 0 to 150 ° C.
  • the reaction time of the hydrolysis reaction is appropriately selected depending on the conditions such as the reaction temperature, but is preferably 1 to 30 hours.
  • the concentration of the tetrahydroisoquinoline derivative (XIII) used for the hydrolysis reaction at the start of the reaction is preferably 1 mmol / L to 1 mol / L.
  • the medicament, ROR ⁇ antagonist and therapeutic or preventive agent for autoimmune diseases of the present invention contain anilide derivative (I) or a hydrate thereof, or a pharmacologically acceptable salt thereof as an active ingredient It is characterized by The above-mentioned autoimmune disease is preferably psoriasis.
  • the “ROR ⁇ antagonist” means a compound having the function of suppressing the function of ROR ⁇ to abolish or attenuate its activity.
  • Autoimmune disease is a general term for diseases in which excessive immune reaction causes symptoms by attacking normal cells and tissues of the patient, and includes, for example, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus Inflammatory bowel disease, ankylosing spondylitis, uveitis, polymyalgia rheumatica, scleroderma, vasculitis, pemphigus, pemphigus or dermatomyositis.
  • the autoimmune diseases of the present invention also include acne, vitiligo or alopecia areata.
  • Allergic disease is a disease derived from the occurrence of excessive immune reaction against a specific antigen, such as allergic dermatitis, contact dermatitis, atopic dermatitis, allergic rhinitis (pollen Disease, allergic conjunctivitis, allergic gastroenteritis, bronchial asthma, childhood asthma or food allergy.
  • Psoriasis is an inflammatory disease of the skin associated with infiltration and activation of immune cells and concomitant epidermal hyperplasia. Typically, white scales adhere thickly on a red rash in various places throughout the body, causing symptoms of scaling that may fall off. Psoriasis includes, for example, psoriasis vulgaris, pustular psoriasis, arthritic psoriasis, psoriatic psoriasis, psoriatic erythroderma.
  • the anilide derivative (I) or a hydrate thereof, or a pharmacologically acceptable salt thereof is characterized in that the function of ROR ⁇ is suppressed by inhibiting the binding of ROR ⁇ to a coactivator.
  • ROR ⁇ is involved in various diseases, and it is known that improvement in the condition or amelioration of symptoms can be expected by suppression of its function. Therefore, the anilide derivative (I) or a hydrate thereof or these drugs Physiologically acceptable salts may be used as medicaments for diseases for which improvement of the pathological condition or amelioration of symptoms can be expected by suppressing the function of ROR ⁇ , particularly as a therapeutic agent or preventive agent for autoimmune diseases or allergic diseases it can.
  • the therapeutic agent or prophylactic agent for the above-mentioned autoimmune diseases is preferably multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, ankylosing spondylitis, uveitis, polymyalgia rheumatica
  • Evaluation of the anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof having ROR ⁇ antagonist activity for inhibiting the binding of ROR ⁇ to a coactivator using an in vitro test it can.
  • an in vitro test for example, a method of evaluating the binding of ROR ⁇ to an agonist (eg, cholesterol) (WO 2012/158784, WO 2013/018695), a ligand binding domain of ROR ⁇ and a coacti Methods for assessing binding to beta can be mentioned (WO 2012/064744, WO 2013/018695).
  • the transcriptional activity inhibitory action of ROR ⁇ can be evaluated using various reporter gene assays (WO 2012/158784, WO 2012/064744, WO 2013/018695).
  • anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof suppresses the function of ROR ⁇ can be obtained by using lymphocyte cells derived from various organs such as spleen or peripheral blood. Production of IL-17 or Th17 cell differentiation can be evaluated as an index.
  • a method using IL-17 production as an index for example, a method of measuring IL-17 production by IL-23 stimulation using mouse splenocytes can be mentioned (The Journal of Biological Chemistry, 2003, 278) , No. 3, p. 1910-1914).
  • Th17 cell differentiation for example, various cytokines (eg, IL-1 ⁇ , IL-6, IL-23 and / or TGF are used, using CD4 positive naive T cells derived from mouse splenocytes or human PBMC). Stimulate with - ⁇ ) and various antibodies (eg, anti-CD3 antibody, anti-CD28 antibody, anti-IL-4 antibody, anti-IFN- ⁇ antibody and / or anti-IL-2 antibody) to differentiate to Th17 and produce IL-17 The method includes measuring the amount or the proportion of IL-17 positive cells etc. (WO 2012/158784, WO 2013/018695).
  • cytokines eg, IL-1 ⁇ , IL-6, IL-23 and / or TGF
  • CD4 positive naive T cells derived from mouse splenocytes or human PBMC.
  • various antibodies eg, anti-CD3 antibody, anti-CD28 antibody, anti-IL-4 antibody, anti-IFN- ⁇ antibody and / or anti-IL-2 antibody
  • the effectiveness of the anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof for the treatment or prevention of an autoimmune disease can be evaluated using a pathological model.
  • a pathological model for example, experimental autoimmune encephalomyelitis model (Journal of Neuroscience Research, 2006, 84, pages 1225-1234), imiquimod-induced psoriasis model (Journal of Immunology, 2009, 182) , P. 5836-5845), collagen arthritis model (Annual Review of Immunology, 1984, Volume 2, 199-218), spontaneous lupus erythematosus model (Nature, volume 404, p. 2000).
  • anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof for treating or preventing allergic disease can be evaluated using a pathological model.
  • a pathological model for example, dinitrofluorobenzene (hereinafter, DNFB) -induced allergic dermatitis model (Pharmacological Reports, 2013, 65, p. 1237-1246), oxazolone-induced atopic dermatitis model (Journal of Investigative) Dermatology, 2014, vol. 134, p. 2122-2130), ovalbumin-induced allergic rhinitis model (Journal of Animal Science, 2010, vol. 81, p.
  • DNFB dinitrofluorobenzene
  • the DNFB-induced allergic dermatitis model is common as a model of allergic dermatitis, in particular as a contact dermatitis model.
  • the oxazolone-induced atopic dermatitis model is common as a model of atopic dermatitis.
  • the efficacy of the anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof for treating or preventing autoimmune diseases or allergic diseases can be determined, for example, using the in vitro test described above, for example
  • the decrease in the amount of binding between the ligand binding domain of ROR ⁇ and the coactivator, or the decrease in the amount of IL-17 produced, which is an indicator of the function of ROR ⁇ , can be evaluated as an indicator.
  • the efficacy for treatment or prevention of multiple sclerosis can be evaluated using, for example, a decrease in neurological symptom score, which is a characteristic index of multiple sclerosis, using the above-mentioned experimental autoimmune encephalomyelitis model. It can be evaluated.
  • the efficacy for treatment or prevention of psoriasis may be evaluated using, for example, the reduction in thickness of skin such as auricle or the like, which increases with the progression of symptoms of the psoriasis model, using the imiquimod-induced psoriasis model described above as an indicator. it can.
  • the efficacy for treatment or prevention of allergic dermatitis, particularly contact dermatitis is increased using, for example, the above-mentioned DNFB-induced allergic dermatitis model, such as the auricle, etc., along with the progress of skin inflammation.
  • the decrease in skin thickness can be evaluated as an index.
  • the efficacy for the treatment or prevention of atopic dermatitis is, for example, using the above-mentioned oxazolone-induced atopic dermatitis model to decrease the thickness of the skin such as the auricle that increases with the progress of skin inflammation. It can be evaluated on indicators.
  • the anilide derivative (I) or a hydrate thereof, or a pharmacologically acceptable salt thereof is a mammal (eg, mouse, rat, hamster, rabbit, dog, cat, monkey, cow, sheep or human) In particular, when it is administered to humans, it can be used as a useful medicament (in particular, a therapeutic or preventive agent for autoimmune diseases or allergic diseases).
  • a useful medicament in particular, a therapeutic or preventive agent for autoimmune diseases or allergic diseases.
  • the anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof is clinically used as a medicament
  • the anilide derivative (I) or a hydrate thereof or a drug thereof The physiologically acceptable salt can be administered orally or parenterally as it is or in combination with a pharmacologically acceptable carrier.
  • binders such as an agent, an emulsifying agent, a surfactant, a suspending agent, a diluent or an isotonic agent may be appropriately mixed.
  • Pharmaceutically acceptable carriers include these additives.
  • the above-mentioned medicament can be manufactured by a usual method using appropriately these pharmaceutical carriers.
  • the dosage form of the above-mentioned medicine includes, for example, oral preparations such as tablets, capsules, granules, powders or syrups, parenteral preparations such as inhalants, injections, suppositories or solutions, or topical administration.
  • oral preparations such as tablets, capsules, granules, powders or syrups
  • parenteral preparations such as inhalants, injections, suppositories or solutions, or topical administration.
  • An ointment, a cream or a patch may be mentioned.
  • it may be a known sustained release preparation.
  • Binders include, for example, syrup, gelatin, gum arabic, sorbitol, polyvinyl chloride or tragacanth.
  • Excipients include, for example, sugar, lactose, corn starch, calcium phosphate, sorbitol or glycine.
  • lubricant for example, magnesium stearate, calcium stearate, polyethylene glycol, talc or silica can be mentioned.
  • Disintegrants include, for example, starch or calcium carbonate.
  • Sweetening agents include, for example, glucose, fructose, invert sugar, sorbitol, xylitol, glycerin or simple syrup.
  • the above-mentioned medicament preferably contains 0.00001 to 90% by weight, preferably 0.01 to 70% by weight, of the anilide derivative (I) or a hydrate thereof, or a pharmacologically acceptable salt thereof. It is more preferable to do.
  • the dose is appropriately selected according to the patient's condition, age and body weight, and administration method, but as an active ingredient amount for adults, 0.1 ⁇ g to 1 g per day for injections and 1 for oral preparations
  • the amount is preferably 1 ⁇ g to 10 g per day, and in the case of a patch, 1 ⁇ g to 10 g per day, each of which can be administered once or several times.
  • the above-mentioned medicines may be used together with other medicines in appropriate amounts or in combination for complementation or enhancement of their therapeutic or preventive effects or reduction of dosage.
  • the compounds used for the synthesis of the compounds of Reference Examples and Examples were commercially available compounds that were not described in the synthesis method.
  • the “room temperature” in the following Reference Examples and Examples usually indicates about 10 ° C. to about 35 ° C. % Indicates mol / mol% for yield, volume% for solvents used in column chromatography and high performance liquid chromatography, and weight% unless otherwise specified.
  • the solvent name shown in the NMR data indicates the solvent used for the measurement.
  • the 400 MHz NMR spectrum was measured using a JNM-AL400 nuclear magnetic resonance apparatus (Nippon Denshi Co., Ltd.) or a JNM-ECS400 nuclear magnetic resonance apparatus (Nippon Denshi Co., Ltd.).
  • Silica gel used silica gel 60 (Merck), amine silica gel used amine silica gel DM 1020 (Fuji Silysia Chemical Ltd.), and chromatography used YFLC W-prep 2 XY (Yamazen Co.).
  • Reference Example 4 Synthesis of 2,2,2-trifluoro-1- (7-methyl-3,4-dihydroisoquinolin-2 (1H) -yl) ethan-1-one: The compound of Reference Example 3 (0.525 g, 2.27 mmol) and paraformaldehyde (0.102 g, 3.41 mmol) are added to a mixture of concentrated sulfuric acid (0.454 mL) and acetic acid (2.27 mL) at 0 ° C. The After stirring at room temperature for 36 hours, the reaction solution was added to ice water and extracted with ethyl acetate.
  • Reference Example 5 Synthesis of 7-methyl-1,2,3,4-tetrahydroisoquinoline: The compound of Reference Example 4 (0.335 g, 1.38 mmol) was dissolved in ethanol (4.17 mL), and 2M aqueous sodium hydroxide solution (3.79 mL) was added at 0 ° C. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure, distilled water was added, and the mixture was extracted with ethyl acetate.
  • Reference Example 6 Synthesis of 2- (2-chloro-4-nitrobenzyl) -7-methyl-1,2,3,4-tetrahydroisoquinoline: The compound of Reference Example 5 (0.184 g, 1.25 mmol) is dissolved in dichloromethane (3.75 mL), and the compound of Reference Example 1 (0.230 g, 1.25 mmol) and acetic acid (0.0354 mL) are added at room temperature. The After stirring for 10 minutes at room temperature, sodium triacetoxyborohydride (0.393 g, 1.86 mmol) was added at 0 ° C. After stirring at room temperature for 2 hours, to the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform.
  • Reference Example 7 Synthesis of 3-chloro-4-((7-methyl-3,4-dihydroisoquinolin-2 (1H) -yl) methyl) aniline: The compound of Reference Example 6 (0.335 g, 1.06 mmol) is dissolved in THF (1.06 mL), ethanol (1.06 mL), distilled water (1.06 mL), iron powder (0.295 g, 5.29 mmol) ) And acetic acid (0.303 mL, 5.29 mmol) were added at room temperature. After stirring at 50 ° C. for 2 hours, to the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform.
  • the crude product obtained was used for the subsequent reaction without purification.
  • the above crude product was dissolved in dichloromethane (297 mL) and metachloroperbenzoic acid (46.2 g, 267 mmol) was added at 0 ° C. After stirring at room temperature for 16 hours, the reaction solution is filtered, and the filtrate is washed with 1 M aqueous sodium hydroxide solution, distilled water and saturated brine, dried over anhydrous sodium sulfate and filtered, and the filtrate is concentrated under reduced pressure.
  • Reference Example 9 Synthesis of 2- (4- (ethylsulfonyl) phenyl) acetic acid: The compound of Reference Example 8 (18.2 g, 71.1 mmol) was dissolved in ethanol (131 mL) and distilled water (131 mL), and sodium hydroxide (10.8 g, 270 mmol) was added at 0 ° C. After stirring at room temperature for 14 hours, concentrated hydrochloric acid was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure.
  • Example 1 N- (3-Chloro-4-((7-methyl-3,4-dihydroisoquinolin-2 (1H) -yl) methyl) phenyl) -2- (4- (ethylsulfonyl) phenyl) Synthesis of acetamide:
  • the compound of Reference Example 7 (0.0400 g, 0.139 mmol) and the compound of Reference Example 9 (0.0382 g, 0.167 mmol) are dissolved in DMF (0.465 mL), and HATU (0.0636 g, 0.167 mmol) is dissolved.
  • diisopropylethylamine (0.0365 mL, 0.209 mmol) were added at room temperature.
  • Reference Example 12 Synthesis of 7- (trifluoromethyl) -1,2,3,4-tetrahydroisoquinoline: The compound of Reference Example 11 (0.400 g, 1.35 mmol) was dissolved in ethanol (4.08 mL), and 2M aqueous sodium hydroxide solution (3.70 mL) was added at 0 ° C. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure, distilled water was added, and the mixture was extracted with ethyl acetate.
  • Reference Example 13 Synthesis of 2- (2-chloro-4-nitrobenzyl) -7- (trifluoromethyl) -1,2,3,4-tetrahydroisoquinoline:
  • the compound of Reference Example 12 (10.0 g, 49.7 mmol) was dissolved in dichloromethane (148 mL), and the compound of Reference Example 1 (9.04 g, 49.7 mmol) and acetic acid (1.40 mL) were added at room temperature. After stirring for 10 minutes at room temperature, sodium triacetoxyborohydride (15.5 g, 73.1 mmol) was added at 0 ° C. After stirring at room temperature for 14 hours, to the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform.
  • Reference Example 14 Synthesis of 3-chloro-4-((7- (trifluoromethyl) -3,4-dihydroisoquinolin-2 (1H) -yl) methyl) aniline: The compound of Reference Example 13 (15.6 g, 42.1 mmol) is dissolved in THF (42.1 mL), ethanol (42.1 mL), distilled water (42.1 mL), iron powder (11.8 g, 210 mmol) and Acetic acid (12.0 mL, 210 mmol) was added at room temperature. After stirring at 50 ° C. for 1.5 hours, to the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform.
  • Example 2 N- (3-Chloro-4-((7- (trifluoromethyl) -3,4-dihydroisoquinolin-2 (1H) -yl) methyl) phenyl) -2- (4- (ethyl) Synthesis of sulfonyl) phenyl) acetamide: Using the compound of Reference Example 14 instead of the compound of Reference Example 7, and using the same procedure as Example 1 except for the above, the title compound (the compound of Example 2 below) (0.0475 g, 0.0862 mmol, 65) %) As a white solid.
  • Reference Example 15 Synthesis of 2- (2-fluoro-4-nitrobenzyl) -7- (trifluoromethyl) -1,2,3,4-tetrahydroisoquinoline: Using the compound of Reference Example 2 in place of the compound of Reference Example 1 and the compound of Reference Example 12 instead of the compound of Reference Example 5 and using the same procedure as in Reference Example 6 except the above, the title compound (hereinafter referred to as Reference) The compound of Example 15 (0.126 g, 0.356 mmol, 79%) was obtained as a light brown solid.
  • Reference Example 16 Synthesis of 3-fluoro-4-((7- (trifluoromethyl) -3,4-dihydroisoquinolin-2 (1H) -yl) methyl) aniline: Using the compound of Reference Example 15 instead of the compound of Reference Example 6, and according to the same procedure as Reference Example 7 except for this, the title compound (hereinafter, the compound of Reference Example 16) (0.0695 g, 0.214 mmol, 61) %) As a yellow oil.
  • Example 3 2- (4- (ethylsulfonyl) phenyl) -N- (3-fluoro-4-((7- (trifluoromethyl) -3,4-dihydroisoquinolin-2 (1H) -yl) Synthesis of methyl) phenyl) acetamide: Using the compound of Reference Example 16 instead of the compound of Reference Example 7, and using the same procedure as Example 1 except the above, the title compound (the compound of Example 3 below) (0.0326 g, 0.0610 mmol, 66) %) As a white solid.
  • Reference Example 18 Synthesis of 2,2,2-trifluoro-1- (6- (trifluoromethyl) -3,4-dihydroisoquinolin-2 (1H) -yl) ethan-1-one: The compound of Reference Example 17 (1.00 g, 3.51 mmol) and paraformaldehyde (0.158 g, 5.26 mmol) were added to a mixture of concentrated sulfuric acid (6.54 mL) and acetic acid (5.02 mL) at 0 ° C. The After stirring at room temperature for 17 hours, the reaction solution was added to ice water and extracted with ethyl acetate.
  • Reference Example 19 Synthesis of 6- (trifluoromethyl) -1,2,3,4-tetrahydroisoquinoline: The compound of Reference Example 18 (0.300 g, 1.01 mmol) was dissolved in ethanol (3.06 mL), and 2 M aqueous sodium hydroxide solution (2.78 mL) was added at 0 ° C. After stirring at room temperature for 7 hours, the reaction mixture was concentrated under reduced pressure, distilled water was added, and the mixture was extracted with ethyl acetate.
  • Reference Example 20 Synthesis of 2- (2-chloro-4-nitrobenzyl) -6- (trifluoromethyl) -1,2,3,4-tetrahydroisoquinoline: The compound of Reference Example 19 (7.50 g, 37.3 mmol) was dissolved in dichloromethane (113 mL), and the compound of Reference Example 1 (6.92 g, 37.3 mmol) and acetic acid (1.07 mL) were added at room temperature. After stirring for 15 minutes at room temperature, sodium triacetoxyborohydride (11.9 g, 55.9 mmol) was added at 0 ° C. After stirring at room temperature for 4 hours, to the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform.
  • Reference Example 21 Synthesis of 3-chloro-4-((6- (trifluoromethyl) -3,4-dihydroisoquinolin-2 (1H) -yl) methyl) aniline: The compound of Reference Example 20 (11.5 g, 31.0 mmol) is dissolved in THF (38.8 mL), ethanol (38.8 mL), distilled water (38.8 mL), iron powder (8.66 g, 155 mmol) and Acetic acid (8.88 mL, 155 mmol) was added at room temperature. After stirring at 50 ° C. for 2.5 hours, a saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform.
  • Example 4 N- (3-Chloro-4-((6- (trifluoromethyl) -3,4-dihydroisoquinolin-2 (1H) -yl) methyl) phenyl) -2- (4- (ethyl) Synthesis of sulfonyl) phenyl) acetamide:
  • the compound of Reference Example 21 (8.00 g, 23.5 mmol) and the compound of Reference Example 9 (5.41 g, 23.7 mmol) are dissolved in DMF (78.0 mL), and HATU (10.7 g, 28.2 mmol) And diisopropylethylamine (6.15 mL, 35.2 mmol) were added at room temperature.
  • Reference Example 22 Synthesis of 1- (2-chloro-4-nitrobenzyl) indoline: The title compound (hereinafter, the compound of Reference Example 22) (0.406 g, 1.41 mmol, 84%) was browned by using indoline instead of the compound of Reference Example 5 and using the same procedure as in Reference Example 6 except the above. Obtained as a solid.
  • Reference Example 23 Synthesis of 3-chloro-4- (indoline-1-ylmethyl) aniline: Using the compound of Reference Example 22 instead of the compound of Reference Example 6, and according to the same procedure as Reference Example 7 except the above, the title compound (hereinafter, the compound of Reference Example 23) (0.139 g, 0.537 mmol, 52 %) As a colorless oil.
  • Example 5 Synthesis of N- (3-Chloro-4- (indoline-1-ylmethyl) phenyl) -2- (4- (ethylsulfonyl) phenyl) acetamide: Using the compound of Reference Example 23 instead of the compound of Reference Example 7, and using the same procedure as Example 1 except for the above, the title compound (the compound of Example 5 below) (0.0406 g, 0.0866 mmol, 75) %) As a white solid.
  • Reference Example 24 Synthesis of 1- (2-chloro-4-nitrobenzyl) -5-methylindoline: The title compound (hereinafter, the compound of Reference Example 24) (0.407 g, 1.34 mmol, 90%) was prepared by using 5-methylindoline instead of the compound of Reference Example 5 and using the same procedure as in Reference Example 6 except the above. ) As a brown solid.
  • Reference Example 25 Synthesis of 3-chloro-4-((5-methylindoline-1-yl) methyl) aniline: Using the compound of Reference Example 24 instead of the compound of Reference Example 6, and according to the same procedure as Reference Example 7 except for this, the title compound (hereinafter, the compound of Reference Example 25) (0.307 g, 1.13 mmol, 85 %) As a white solid.
  • Example 6 Synthesis of N- (3-Chloro-4-((5-methylindoline-1-yl) methyl) phenyl) -2- (4- (ethylsulfonyl) phenyl) acetamide: Using the compound of Reference Example 25 instead of the compound of Reference Example 7, and using the same procedure as Example 1 except the above, the title compound (the compound of Example 6 below) (0.0303 g, 0.0627 mmol, 57) %) As a white solid.
  • Reference Example 27 Synthesis of 3-chloro-4- (isoindoline-2-ylmethyl) aniline: Using the compound of Reference Example 26 instead of the compound of Reference Example 6, and according to the same procedure as Reference Example 7 except for this, the title compound (hereinafter, the compound of Reference Example 27) (0.181 g, 0.700 mmol, 67 %) As a brown solid.
  • Example 7 Synthesis of N- (3-Chloro-4- (isoindoline-2-ylmethyl) phenyl) -2- (4- (ethylsulfonyl) phenyl) acetamide: Using the compound of Reference Example 27 instead of the compound of Reference Example 7, and using the same procedure as Example 1 except the above, the title compound (the compound of Example 7 below) (0.0233 g, 0.0497 mmol, 43) %) As a white solid.
  • Reference Example 29 Synthesis of 3-chloro-4-((5- (trifluoromethyl) isoindolin-2-yl) methyl) aniline: Using the compound of Reference Example 28 instead of the compound of Reference Example 6, and according to the same procedure as Reference Example 7 except the above, the title compound (hereinafter, the compound of Reference Example 29) (0.0568 g, 0.174 mmol, 59) %) As a brown oil.
  • Example 8 Synthesis of N- (3-Chloro-4-((5- (trifluoromethyl) isoindoline-2-yl) methyl) phenyl) -2- (4- (ethylsulfonyl) phenyl) acetamide: Using the compound of Reference Example 29 instead of the compound of Reference Example 7, and using the same procedure as Example 1 except the above, the title compound (the compound of Example 8 below) (0.0115 g, 0.0214 mmol, 25) %) As a white solid.
  • Reference Example 31 Synthesis of 3-chloro-4- (3,4-dihydroisoquinolin-2 (1H) -yl) aniline: Using the compound of Reference Example 30 instead of the compound of Reference Example 6, and according to the same procedure as Reference Example 7 except for this, the title compound (hereinafter, the compound of Reference Example 31) (0.872 g, 3.37 mmol, 97 %) As a pale red oil.
  • Example 9 Synthesis of N- (3-Chloro-4- (3,4-dihydroisoquinolin-2 (1H) -yl) phenyl) -2- (4- (ethylsulfonyl) phenyl) acetamide: Using the compound of Reference Example 31 instead of the compound of Reference Example 7, and using the same procedure as Example 1 except the above, the title compound (the compound of Example 9 below) (0.0537 g, 0.114 mmol, 59) %) As a white solid.
  • the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure.
  • the crude product obtained was used for the subsequent reaction without purification.
  • the above crude product is dissolved in THF (7.01 mL), ethanol (7.01 mL), distilled water (7.01 mL), iron powder (0.313 g, 5.61 mmol) and acetic acid (0.802 mL, 14) .0 mmol) was added at room temperature. After stirring at 70 ° C. for 3 hours, to the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform.
  • Example 10 N- (3-Chloro-4- (7- (trifluoromethyl) -3,4-dihydroisoquinolin-2 (1H) -yl) phenyl) -2- (4- (ethylsulfonyl) phenyl ) Synthesis of acetamide: Using the compound of Reference Example 32 instead of the compound of Reference Example 7, and using the same procedure as Example 1 except the above, the title compound (the compound of Example 10) (0.0571 g, 0.106 mmol, 69) %) As a white solid.
  • Reference Example 33 Synthesis of 2- (2-chloro-4-nitrophenyl) -6- (trifluoromethyl) -1,2,3,4-tetrahydroisoquinoline: A procedure similar to Reference Example 30 is used except that 6- (trifluoromethyl) -1,2,3,4-tetrahydroisoquinoline hydrochloride is used instead of 1,2,3,4-tetrahydroisoquinoline hydrochloride.
  • the title compound (hereinafter, the compound of Reference Example 33) (1.10 g, 3.08 mmol, 85%) was obtained as a yellow-brown oil.
  • Reference Example 34 Synthesis of 3-chloro-4- (6- (trifluoromethyl) -3,4-dihydroisoquinolin-2 (1H) -yl) aniline: Using the compound of Reference Example 33 instead of the compound of Reference Example 6, and according to the same procedure as Reference Example 7 except for this, the title compound (hereinafter, the compound of Reference Example 34) (0.940 g, 2.88 mmol, 99) %) As a tan oil.
  • Example 11 N- (3-Chloro-4- (6- (trifluoromethyl) -3,4-dihydroisoquinolin-2 (1H) -yl) phenyl) -2- (4- (ethylsulfonyl) phenyl ) Synthesis of acetamide: Using the compound of Reference Example 34 instead of the compound of Reference Example 7, and according to the same procedure as Example 1 except the above, the title compound (the compound of Example 11 below) (0.0820 g, 0.153 mmol, quantitative) ) As a yellow solid.
  • Reference Example 35 Synthesis of 2- (2-chloro-4-nitrobenzyl) -1,2,3,4-tetrahydroisoquinoline: The title compound (hereinafter, the compound of Reference Example 35) (0.370 g), using 1,2,3,4-tetrahydroisoquinoline instead of the compound of Reference Example 5, and using the same procedure as in Reference Example 6 except the above. 1.22 mmol, 81%) were obtained as a yellow solid.
  • Reference Example 36 Synthesis of 3-chloro-4-((3,4-dihydroisoquinolin-2 (1H) -yl) methyl) aniline: Using the compound of Reference Example 35 instead of the compound of Reference Example 6, and according to the same procedure as Reference Example 7 except for this, the title compound (hereinafter, the compound of Reference Example 36) (0.306 g, 1.12 mmol, 92 %) As a white solid.
  • Example 12 Synthesis of N- (3-Chloro-4-((3,4-dihydroisoquinolin-2 (1H) -yl) methyl) phenyl) -2- (4- (ethylsulfonyl) phenyl) acetamide: Using the compound of Reference Example 36 instead of the compound of Reference Example 7, and using the same procedure as Example 1 except the above, the title compound (the compound of Example 12 below) (0.0293 g, 0.0607 mmol, 55) %) As a white solid.
  • ROR ⁇ -coactivator binding inhibitory action The inhibitory effect of the anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof on the binding of the ligand binding domain of ROR ⁇ (hereinafter referred to as ROR ⁇ -LBD) to a coactivator It was evaluated using the resolved fluorescence energy transfer LanthaScreen TM of (TR-FRET) invitrogen company using the TR-FRET Retinoid-Related Orphan Receptor (ROR) gamma Coactivator Assay kit.
  • test compound was dissolved in DMSO and then diluted with a 5 mmol / L DTT-containing TR-FRET Coregulator Buffer D (invitogen) to a final DMSO concentration of 1%.
  • a 5 mmol / L DTT-containing TR-FRET Coregulator Buffer D invitogen
  • To each well of a 384 well black plate (Corning), 4 nmol / L GST-fused ROR ⁇ -LBD (invitogen) diluted with the above buffer and a test compound were added.
  • a test compound-free and GST-fused ROR ⁇ -LBD-free (background), and a test compound-free and GST-fused ROR ⁇ -LBD-added (control) wells were provided.
  • ROR ⁇ -coactivator binding inhibition rate (1 ⁇ ((Fold change upon addition of test compound) ⁇ (Fold change)) / ((Fold change) ⁇ (Fold change) )) ⁇ 100 ...
  • the ROR ⁇ -coactivator binding inhibition rate (%) at 33 ⁇ mol / L of the test compound is shown in Table 2.
  • anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof significantly inhibits the binding of ROR ⁇ -LBD to a coactivator.
  • Example 14 Inhibitory Effect on IL-17 Production in Mouse Splenocytes: The suppressive effect of anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof on IL-23 production by IL-23 stimulation using mouse splenocytes, The Journal of Biological Chemistry 2003, 278, No. 3, p. The method described in 1910-1914 was partially modified and evaluated.
  • a single cell suspension was prepared from the spleen of a C57BL / 6J mouse (male, 8 to 26 weeks old) (Nihon Charles River Co., Ltd.), and splenocytes were prepared using Histopaque-1083 (Sigma).
  • the culture medium is RPMI 1640 medium (Gibco), 10% FBS (Gibco), 50 U / mL penicillin, 50 ⁇ g / mL streptomycin (Gibco), 50 ⁇ mol / L 2-mercaptoethanol (Gibco) and 100 U / mL human IL- 2 (Cell Science Research Institute, Inc.) was added and used.
  • the test compound was dissolved in DMSO and then diluted to a final concentration of 0.1% in culture medium.
  • Splenocytes (3 ⁇ 10 5 cells / well) prepared in culture medium are seeded in wells of a 96 well flat bottom plate (Corning Co.), and a test compound and 10 ng / mL of human IL-23 (R & D systems) are added. Te, 37 ° C., and cultured for 3 days under the conditions of 5% CO 2. In addition, a human IL-23 non-added and a test compound non-added, and a human IL-23 added and test compound non-added well were provided. After completion of the culture, the culture supernatant was collected, and the amount of IL-17 produced in the supernatant was quantified by ELISA (R & D systems).
  • IL-17 production inhibition rate (%) was calculated from the following formula 2.
  • IL-17 production suppression rate (%) (1- ((IL-23 production amount with addition of IL-23 and test compound))-(IL-17 production amount without IL-23 addition and without test compound) )) / ((The amount of IL-17 produced with addition of IL-23 and no test compound)-(the amount of IL-17 produced without addition of IL-23 and no test compound))) ⁇ 100 ⁇
  • Formula 2 (1- ((IL-23 production amount with addition of IL-23 and test compound))-(IL-17 production amount without IL-23 addition and without test compound) ))) / ((The amount of IL-17 produced with addition of IL-23 and no test compound)-(the amount of IL-17 produced without addition of IL-23 and no test compound))) ⁇ 100 ⁇
  • Formula 2 (1- ((IL-23 production amount with addition of IL-23 and test compound))-(IL-17 production amount without IL-23 addition and without test
  • the inhibition ratio (%) of IL-17 production at 5 ⁇ mol / L of the test compound is shown in Table 3.
  • the inhibition ratio (%) of IL-17 production at 0.3 ⁇ mol / L of the test compound is shown in Table 4.
  • Example 15 Suppressive effect on imiquimod-induced mouse psoriasis model: The effect of the anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof in an imiquimod-induced mouse psoriasis model was evaluated using an increase in auricle thickness as an indicator of symptom deterioration.
  • the imiquimod-induced mouse psoriasis model was prepared by partially modifying the method of Schaper et al. (The Journal of Dermatological Science, 2013, 71, No. 1, p. 29-36).
  • BALB / c mice male, 7 weeks old (Nihon Charles River Co., Ltd.) were used at 8 weeks of age after preliminary breeding.
  • 5 mg of Becelna cream was applied once a day on the outside of the left and right auricle of the mouse for 8 days from the first day of imiquimod administration (hereinafter, induction day) to 7 days after induction.
  • induction day first day of imiquimod administration
  • the test compound was administered at a dose of 10 mg / kg once a day to the mice for 5 days from the 3rd day to the 7th day after induction.
  • the compound of Example 4 was used as a test compound.
  • the compound of Example 4 was suspended in 0.5 w / v% methylcellulose solution and orally administered.
  • the group to which the compound of Example 4 was administered to mice was taken as the compound administration group of Example 4.
  • the vehicle administration group was similarly administered the solvent (0.5 w / v% methylcellulose solution) of each test compound.
  • the thickness of the left and right auricles before (immune) administration of imiquimod and the thickness of the left and right auricles on day 8 after induction were measured using a digital micrometer (Mitsutoyo).
  • the average thickness of the left and right auricles was taken as the auricle thickness, and the change (the auricular thickness on the 8th day after induction-the auricular thickness before the induction) was used as an index for drug efficacy evaluation.
  • the results are shown in FIG.
  • the “solvent” on the horizontal axis represents a solvent administration group, and the “compound of Example 4” represents a compound administration group of Example 4. * Indicates statistically significant (*: P ⁇ 0.05) in comparison with the vehicle administration group (Student's t-test).
  • the auricle thickness at day 8 after induction in the solvent administration group increased by 0.26 mm relative to the auricle thickness before induction. This increase in auricular thickness was statistically significantly suppressed by the administration of the compound of Example 4.
  • anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof exhibits a remarkable symptom suppressing effect on psoriasis.
  • the anilide derivative (I) or a hydrate thereof or a pharmacologically acceptable salt thereof according to the present invention has excellent ROR ⁇ antagonist activity, so that the improvement or symptoms of the pathological condition by suppressing the function of ROR ⁇ It can be used as a medicine for diseases in which a remission of In particular, it can be used as a therapeutic or preventive agent for autoimmune diseases such as psoriasis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Le but de la présente invention est de fournir un nouveau composé qui a une activité antagoniste du récepteur γ orphelin associé au rétinoïde et qui présente un effet réparateur ou un effet prophylactique sur des maladies auto-immunes, y compris le psoriasis. La présente invention concerne le dérivé d'anilide (I) présenté ci-dessous ou un hydrate de celui-ci ou un sel acceptable sur le plan pharmacologique de l'un ou de l'autre.
PCT/JP2018/040211 2017-10-31 2018-10-30 Dérivé d'anilide et son utilisation médicale WO2019088057A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018560051A JPWO2019088057A1 (ja) 2017-10-31 2018-10-30 アニリド誘導体及びその医薬用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-210740 2017-10-31
JP2017210740 2017-10-31

Publications (1)

Publication Number Publication Date
WO2019088057A1 true WO2019088057A1 (fr) 2019-05-09

Family

ID=66331869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/040211 WO2019088057A1 (fr) 2017-10-31 2018-10-30 Dérivé d'anilide et son utilisation médicale

Country Status (3)

Country Link
JP (1) JPWO2019088057A1 (fr)
TW (1) TW201922700A (fr)
WO (1) WO2019088057A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021139595A1 (fr) * 2020-01-06 2021-07-15 东莞市东阳光新药研发有限公司 INHIBITEUR DE RORγT, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160122318A1 (en) * 2014-11-05 2016-05-05 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ror-gamma
WO2016193452A1 (fr) * 2015-06-05 2016-12-08 Lead Pharma Cel Models Ip B.V. Modulateurs de ror gamma (rorγ)
WO2017010399A1 (fr) * 2015-07-10 2017-01-19 塩野義製薬株式会社 COMPOSÉS AYANT DES EFFETS INHIBITEURS DE RORγt ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
WO2017087608A1 (fr) * 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulateurs de ror-gamma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160122318A1 (en) * 2014-11-05 2016-05-05 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ror-gamma
WO2016193452A1 (fr) * 2015-06-05 2016-12-08 Lead Pharma Cel Models Ip B.V. Modulateurs de ror gamma (rorγ)
WO2017010399A1 (fr) * 2015-07-10 2017-01-19 塩野義製薬株式会社 COMPOSÉS AYANT DES EFFETS INHIBITEURS DE RORγt ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
WO2017087608A1 (fr) * 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulateurs de ror-gamma

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021139595A1 (fr) * 2020-01-06 2021-07-15 东莞市东阳光新药研发有限公司 INHIBITEUR DE RORγT, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION

Also Published As

Publication number Publication date
JPWO2019088057A1 (ja) 2020-09-24
TW201922700A (zh) 2019-06-16

Similar Documents

Publication Publication Date Title
US9802945B2 (en) Imidazopyridazine derivatives as modulators of the GABAA receptor activity
JP2007528362A (ja) 置換アリールアルカン酸誘導体及びその用途
CN101723896B (zh) 酪氨酸衍生物类组蛋白去乙酰化酶抑制剂及其应用
US11578058B2 (en) Heterocyclic compounds for inhibiting TYK2 activities
AU2015345259A1 (en) 2-Amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
US20220298112A1 (en) N-(PHENYL)-Indole-3-Sulfonamide Derivatives And Related Compounds As GPR17 Modulators For Treating CNS Disorders Such As Multiple Sclerosis
JP2020189852A (ja) キナーゼ阻害活性を有するベンズヒドロール−ピラゾール誘導体及びその使用
JP2015124178A (ja) 環状アミン誘導体及びその医薬用途
JP7148709B2 (ja) バニン阻害剤としてのヘテロ芳香族化合物
CA2570046A1 (fr) Derives triazole substitues utilises en tant qu'antagonistes de l'oxytocine
WO2021193756A1 (fr) Dérivé inédit de benzimidazole
WO2022057770A1 (fr) Composé pharmaceutique utilisé comme inhibiteur de la kinase jak
TW201331202A (zh) ［１，２，４］三唑并吡啶及其作為磷酸二酯酶抑制劑之用途
JP2011201777A (ja) 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体
WO2019088057A1 (fr) Dérivé d'anilide et son utilisation médicale
JP2023545784A (ja) Ｊａｋキナーゼ阻害剤としての小分子化合物及びその用途
JP5573677B2 (ja) ２，３−ジヒドロ−１ｈ−インデン−２−イルウレア誘導体及びその医薬用途
JPWO2006132192A1 (ja) 新規２−キノロン誘導体
WO2019044940A1 (fr) Dérivé d'amine cyclique et son utilisation à des fins médicales
WO2019151270A1 (fr) Dérivé d'amine cyclique et utilisation pharmaceutique associée
EP4065117A1 (fr) Dérivés d'isoquinoléine destinés à être utilisés dans le traitement du syndrome de carence en glut1
JP2012211086A (ja) 関節リウマチの治療剤又は予防剤
CN101252838A (zh) 新型含异羟肟酸的氨基酸衍生物
TW202034911A (zh) 肥胖症的治療
RU2803938C2 (ru) Новое соединение бензимидазолона и его фармацевтическое применение

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018560051

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18873622

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18873622

Country of ref document: EP

Kind code of ref document: A1